Drugrecure

Drugrecure is a clinical-stage biotechnology company based in South Korea that specializes in the development of small molecule inhibitors for inflammatory and autoimmune diseases. The company's lead program, DR-1501, is a potent and selective dual inhibitor of IRAK1 and IRAK4, designed to address unmet needs in conditions such as atopic dermatitis and hidradenitis suppurativa. By targeting the IRAK signaling pathway, Drugrecure aims to modulate the innate immune response and provide more effective treatments for chronic inflammatory disorders. The company is currently advancing its pipeline through early-stage clinical trials while exploring additional applications in oncology.